Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective study for effectiveness of Etelcalcetide hydrochloride (Parsabiv) on patients treated with hemodialysis

Trial Profile

Prospective study for effectiveness of Etelcalcetide hydrochloride (Parsabiv) on patients treated with hemodialysis

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Sep 2018

At a glance

  • Drugs Etelcalcetide (Primary)
  • Indications Secondary hyperparathyroidism
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Aug 2018 Planned End Date changed from 31 Aug 2019 to 31 Dec 2019.
    • 04 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top